Table III.
Multivariate analysis for serologic response in HM patients.
| Variable | Odds ratio | 95% CI | P |
|---|---|---|---|
| Sex | |||
| Male | 1 | 0·239 | |
| Female | 0·65 | 0·32–1·33 | |
| Age | |||
| <65 years | 1 | 0·679 | |
| ≥65 years | 0·85 | 0·40–1·83 | |
| Diagnosis | |||
| Hodgkin lymphoma | 1 | <0·001 | |
| Aggressive B‐cell lymphomas | 0·54 | 0·15–1·91 | |
| Indolent B‐cell lymphomas or B‐cell chronic lymphocytic leukaemia | 1·33 | 0·36–4·93 | |
| Multiple myeloma | 28·15 | 4·43–178·95 | |
| T‐cell lymphomas | 0·5 | 0·06–3·82 | |
| Disease status | |||
| Remission | 1 | 0·095 | |
| Active | 0·44 | 0·17–1·15 | |
| Type of treatment | |||
| Other therapies | 1 | <0·001 | |
| Anti‐CD20 antibody plus chemotherapy | 0·07 | 0·02–0·22 | |
| Watch and wait or last therapy > 12 months prior | 2·84 | 0·96–8·36 | |
| ALC | |||
| <800 cells/μl | 1 | 0·001 | |
| ≥800 cells/μl | 1·66 | 0·65–4·25 | |
| Not evaluable | 0·17 | 0·04–0·77 | |
| ANC | |||
| <1500 cells/μl | 1 | 0·884 | |
| ≥1500 cells/μl | 1·10 | 0·31–3·96 | |
| IgG | |||
| <600 mg/dl | 1 | 0·510 | |
| ≥600 mg/dl | 1·44 | 0·47–4·47 | |
| Not evaluable or not available | 0·68 | 0·18–2·65 | |
| IgA | |||
| <80 mg/dl | 1 | 0·548 | |
| ≥80 mg/dl | 1·5 | 0·50–4·50 | |
| Not evaluable or not available | 0·49 | 0·06–3·77 | |
| IgM | |||
| <40 mg/dl | 1 | 0·004 | |
| ≥40 mg/dl | 4·31 | 1·52–12·24 | |
| Not evaluable or not available | 17·54 | 1·93–159·03 |
ALC, absolute lymphocytic count; ANC, absolute neutrophilic count; CI, confidence interval.